Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Novel ACE2-blocking antibody protects against all SARS-CoV-2 VOCs

Researchers identify 87G7, a SARS-CoV-2 neutralizing human monoclonal antibody with remarkable broad-spectrum neutralization and protection efficacy.

21 Feb 2022

Monitoring rise of SARS-CoV-2 variants in wastewater using genome sequencing

Researchers conduct genomic wastewater surveillance of SARS-CoV-2 following the emergence of the Alpha and Delta variants in the United Kingdom.

21 Feb 2022

Study reports potently neutralizing mucosal IgA in saliva of BNT162b2 vaccine recipients

researchers determine the strong neutralizing mucosal component emanating from intramuscular administration of an mRNA vaccine.

21 Feb 2022

SARS-CoV-2 Omicron variant prompts system sciences and precision medicine

In a new review study, researchers aimed to describe the emergence of the Omicron variant, its structure, its impact on health and health systems, and the challenges that can be expected due to this variant.

21 Feb 2022

Molecular characteristics of SARS-CoV-2 variants enabling antibody escape

A new review paper published in PLoS Pathogens discusses the new variants and the structural mechanism underlying antibody-mediated neutralization as well as mutational antibody escape.

21 Feb 2022

Mechanisms of IL-6 expression in peripheral monocyte-derived macrophages infected with SARS-CoV-2

Researchers examined the detailed mechanisms of ‘cytokine storm’ that induces ARDS, often resulting in the death of severely ill COVID-19 patients.

21 Feb 2022

Inhalable antibody fragments offer broad protection from SARS-CoV-2 variants

A new study describes a potential new approach to treating COVID-19 in the form of single-chain fragment variable (scFv) antibodies.

20 Feb 2022

Researchers develop novel anti-SARS-CoV-2 Omicron vaccine candidate

Researchers have developed a new vaccine candidate that is specifically targeted against the SARS-CoV-2 Omicron variant.

20 Feb 2022

T-cell responses linked with protection from SARS-CoV-2 infection in vaccinated individuals with or without cancer

T-cell responses directed against the receptor-binding domain of the SARS-CoV-2 spike protein were associated with protection from SARS-CoV-2 infection in vaccinated individuals with or without cancer, with lower T-cell responses observed in patients with blood cancers.

18 Feb 2022

Study characterizes COVID-19 vaccine effectiveness at longer dose intervals

Researchers conducted a prospective cohort study to assess the level and durability of protection offered by two doses of COVID-19 vaccine against SARS-CoV-2 infection in participants with no history of a previous infection.

18 Feb 2022

Study reveals the structural, functional landscape of neutralizing antibodies against SARS-CoV-2 spike protein

The SARS-CoV-2 virus is continuously evolving and structural changes to the virus may impact the efficacy of antibody therapies and vaccines.

18 Feb 2022

SARS-CoV-2 Mpro inhibitor, nirmatrelvir, found to reduce COVID-19 progression and death

In a new study, researchers evaluated the efficacy and safety of nirmatrelvir in mild to moderate COVID-19 patients who were at high risk of severe COVID-19 disease.

18 Feb 2022

The ability of therapeutic monoclonal antibodies to neutralize SARS-CoV-2 Omicron BA.2 variant

Researchers evaluated the neutralizing capacity of the clinically approved mAbs against the SARS-CoV-2 Omicron BA.2 variant.

18 Feb 2022

Study explores efficacy of mRNA vaccine booster doses during the SARS-CoV-2 Omicron wave

Researchers evaluated the efficacy of an mRNA vaccine booster dose against severe acute respiratory syndrome coronavirus-2 during the Omicron surge.

18 Feb 2022

Immunogenicity, efficacy, and safety of BNT162b2 or mRNA1273 fourth dose

A recent study explored the safety, immunogenicity, and VE of the SARS-CoV-2 mRNA BNT162b2 and mRNA1273 vaccines against its Omicron VOC in HCWs in Israel.

18 Feb 2022

mRNA vaccine-induced antibodies shown to be more effective in neutralizing SARS-CoV-2 and its variants than natural immunity

Researchers designed an electrochemiluminescence-based serology test with remarkable sensitivity to precisely quantify the amounts of anti-RBD antibodies in individuals infected with SARS-CoV-2.

18 Feb 2022

Role of quantitative, multiplexed, targeted proteomics in determining variant-specific SARS-CoV-2 antibody response

Researchers developed a ‘bait and capture’ system which was further followed by a multiplexed and targeted proteomic liquid chromatography-tandem mass spectrometry analyses for the comparison of immune correlates in response to vaccination, natural infection, as well as protection against SARS-CoV-2 variants.

18 Feb 2022

Antibody News and Research

Further Reading

Novel ACE2-blocking antibody protects against all SARS-CoV-2 VOCs

Monitoring rise of SARS-CoV-2 variants in wastewater using genome sequencing

Study reports potently neutralizing mucosal IgA in saliva of BNT162b2 vaccine recipients

SARS-CoV-2 Omicron variant prompts system sciences and precision medicine

Molecular characteristics of SARS-CoV-2 variants enabling antibody escape

Mechanisms of IL-6 expression in peripheral monocyte-derived macrophages infected with SARS-CoV-2

Inhalable antibody fragments offer broad protection from SARS-CoV-2 variants

Researchers develop novel anti-SARS-CoV-2 Omicron vaccine candidate

T-cell responses linked with protection from SARS-CoV-2 infection in vaccinated individuals with or without cancer

Study characterizes COVID-19 vaccine effectiveness at longer dose intervals

Study reveals the structural, functional landscape of neutralizing antibodies against SARS-CoV-2 spike protein

SARS-CoV-2 Mpro inhibitor, nirmatrelvir, found to reduce COVID-19 progression and death

The ability of therapeutic monoclonal antibodies to neutralize SARS-CoV-2 Omicron BA.2 variant

Study explores efficacy of mRNA vaccine booster doses during the SARS-CoV-2 Omicron wave

Immunogenicity, efficacy, and safety of BNT162b2 or mRNA1273 fourth dose

mRNA vaccine-induced antibodies shown to be more effective in neutralizing SARS-CoV-2 and its variants than natural immunity

Role of quantitative, multiplexed, targeted proteomics in determining variant-specific SARS-CoV-2 antibody response

Study finds antigenic profile of Omicron RBD is distinct from the prior SARS-CoV-2 variants of concern

Trial of early antiviral therapy for COVID-19 shows no significant benefit

Ensitrelvir, a novel SARS-CoV-2 antiviral

Event guide: 5th Novel Conjugates Summit 2026 eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo